GlassScriptPhysician profile
Gregory William Schall
NPI 1326102203
$10,383.93
in general payments reported to CMS, 2019-2025
47 companies · $1,675 in 2025
The $1,675 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,444 · 2020: $1,089 · 2021: $1,573 · 2022: $1,263 · 2023: $1,431 · 2024: $1,909 · 2025: $1,675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,015.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,845.34 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $943.81 | 2020-2021 | |
| Pfizer INC. | $902.71 | 2019-2025 | |
| Abbvie INC. | $834.74 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $780.68 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $725.97 | 2019-2025 | Repatha, Prolia, Evenity |
| Glaxosmithkline, LLC. | $679.32 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $573.86 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Biohaven Pharmaceutical Holding Company LTD. | $365.35 | 2022 | |
| Phathom Pharmaceuticals, INC. | $319.96 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $277.56 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.26 | 2019-2024 | Ofev |
| Astellas Pharma US INC | $158.33 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $149.92 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $108.79 | 2023-2024 | Quviviq |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $107.11 | 2021-2025 | Nexletol |
| Axsome Therapeutics, INC. | $106.13 | 2023-2025 | Auvelity, Symbravo |
| Allergan, INC. | $105.02 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $97.42 | 2019-2024 | Dificid, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $87.33 | 2019-2023 | |
| Exact Sciences Corporation | $87.03 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $76.74 | 2019-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $67.50 | 2019-2024 | Trintellix |
| Abbott Laboratories | $64.12 | 2021-2025 | Freestyle Libre, Freestyle Libre 3 |
| Shield Therapeutics INC | $54.88 | 2022 | |
| Sanofi-Aventis U.S. LLC | $49.12 | 2019-2023 | |
| Radius Health, INC. | $43.32 | 2024-2025 | Tymlos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.97 | 2020-2023 | Xifaxan |
| Sumitomo Pharma America, INC. | $40.98 | 2023 | Gemtesa |
| Supernus Pharmaceuticals, INC. | $36.30 | 2019-2020 | |
| Optinose US, INC. | $36.08 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $35.89 | 2020-2023 | |
| Almatica Pharma LLC | $35.82 | 2024 | Loreev Xr |
| Amarin Pharma, INC. | $34.84 | 2019-2020 | |
| Averitas Pharma INC. | $30.97 | 2025 | Qutenza |
| Inogen, INC. | $30.71 | 2022-2023 | Inogen At Home Stationary Concentrator |
| Lundbeck LLC | $25.71 | 2025 | Rexulti |
| Eisai INC. | $24.53 | 2020 | |
| Ironwood Pharmaceuticals, INC | $21.52 | 2023 | Linzess |
| Antares Pharma, INC. | $20.95 | 2025 | Xyosted |
| Sunovion Pharmaceuticals INC. | $20.90 | 2021 | |
| Biogen, INC. | $20.36 | 2025 | Zurzuvae |
| Teva Pharmaceuticals USA, INC. | $15.97 | 2024 | Austedo Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.68 | 2025 | |
| Corcept Therapeutics | $14.29 | 2024 | Korlym |
| Dexcom, INC. | $12.77 | 2021 | |
| Genentech USA, INC. | $12.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Schall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.